Compare iShares Self-Driving EV and Tech (IDRV) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Johnson & Johnson — how do they compare? iShares Self-Driving EV and Tech trades at $33.34 (market cap $264.50M), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 2336.8× iShares Self-Driving EV and Tech's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares Self-Driving EV and Tech pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and Johnson & Johnson for 129 Days on average.
| IDRV | JNJ | |
|---|---|---|
Market Cap | $264.50M | $618.09B |
Volume | 48,021 | 6,050,983 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $278.43 |
52-Week Low | $32.68 | $186.00 |
Typical Hold Time | 73 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $33.34, down slightly (-0.06%) with a bearish technical signal. Moving averages indicate selling pressure while oscillators remain neutral. The stock faces resistance at $34 and support at $33. Recent news highlights mixed EV market conditions with strong European demand but weaker US adoption following subsidy changes. Chinese competition and regulatory uncertainties create headwinds for the sector.
The outlook remains cautious given technical weakness and sector challenges. Investment opportunity exists in global EV growth trends, particularly in Europe and China. Key risks include US regulatory uncertainty, Chinese market access restrictions, and volatile oil prices affecting consumer EV adoption decisions.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
